Lucid Diagnostics Inc PRE 14A, filed Apr 18, 2025

Lucid Diagnostics Inc. (LUCD)

PRE 14A 2025-04-18 For: 2025-04-18

Added on October 22, 2026

☒	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐	Definitive Proxy Statement
☐	Definitive Additional Materials
☐	Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12

☒	No fee required.
☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

	1)	Title of each class of securities to which transaction applies:

	2)	Aggregate number of securities to which transaction applies:

	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	4)	Proposed maximum aggregate value of transaction:

	5)	Total fee paid:


☐	Fee paid previously with preliminary materials.
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	1)	Amount Previously Paid:

	2)	Form, Schedule or Registration Statement No.:

	3)	Filing Party:

	4)	Date Filed:

Name	Age	Position
Lishan Aklog, M.D.	59	Chairman and Chief Executive Officer
Dennis M. McGrath	68	Chief Financial Officer
Shaun M. O’Neil	43	President and Chief Operating Officer
Michael A. Gordon	51	General Counsel and Secretary
Stanley N. Lapidus	76	Vice Chairman and Director
James L. Cox, M.D.	82	Director
Dennis A. Matheis	64	Director
Jacque J. Sokolov, M.D.	70	Director
Ronald M. Sparks	70	Director
Debra J. White	63	Director

	Submitted by the Audit Committee:

	Ronald M. Sparks
	Jacque J. Sokolov, M.D.
	Debra J. White

	By Order of the Board of Directors


	Lishan Aklog, M.D.
	Chief Executive Officer and Chairman of the Board

	Chair		Member
Audit Committee	$	27,500	$	17,500
Compensation Committee	$	18,000	$	12,500
Nominating and Corporate Governance Committee	$	12,500	$	7,500
Technology, Compliance and Quality Committee	$	20,000	$	12,500

	Stock Option Grants							Stock Awards
Name	Number of Securities Underlying Stock Options – Exercisable⁽¹⁾		Number of Securities Underlying Stock Options – Unexercisable⁽¹⁾		Stock Option Exercise Price		Stock Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested⁽¹⁾		Market Value of Shares of Units of Stock That Have Not Vested
Stanley N. Lapidus		59,000		—	$	3.95	Feb. 17, 2032		—		—
		116,667		58,333	$	1.31	Jan. 30, 2033		—		—
		50,001		99,999	$	1.25	Feb. 21, 2034		—		—
James L. Cox, M.D.		—		—		—	—		169,320	$	138,673
		59,000		—	$	3.95	Feb. 17, 2032		—		—
		116,667		58,333	$	1.31	Jan. 30, 2033		—		—
		50,001		99,999	$	1.25	Feb. 21, 2034		—		—
Jacque J. Sokolov, M.D.		—		—		—	—		84,660	$	69,337
		59,000		—	$	3.95	Feb. 17, 2032		—		—
		116,667		58,333	$	1.31	Jan. 30, 2033		—		—
		50,001		99,999	$	1.25	Feb. 21, 2034		—		—
Ronald M. Sparks									84,660	$	69,337
		59,000		—	$	3.95	Feb. 17, 2032		—		—
		116,667		58,333	$	1.31	Jan. 30, 2033		—		—
		50,001		99,999	$	1.25	Feb. 21, 2034		—		—
Debra J. White		66,666		13,334	$	2.95	Aug. 1, 2032		—		—
		116,667		58,333	$	1.31	Jan. 30, 2033		—		—
		50,001		99,999	$	1.25	Feb. 21, 2034		—		—
Dennis A. Matheis		—		241,500	$	1.03	May 6, 2034		—		—

Named Executive Officer/Principal Position	Year	Salary		Stock Awards⁽²⁾		Option Awards⁽²⁾		Bonus		All Other Compensation		Total
Lishan Aklog, M.D.⁽¹⁾	2024	$	300,000	$	412,000	$	—	$	—	$	—	$	712,000
Chairman of the Board and Chief Executive Officer	2023	$	300,000	$	—	$	—	$	—	$	—	$	300,000
Dennis M. McGrath⁽¹⁾	2024	$	225,000	$	412,000	$	—	$	—	$	—	$	637,000
Chief Financial Officer	2023	$	225,000	$	—	$	—	$	—	$	—	$	225,000
Shaun M. O’Neil⁽¹⁾	2024	$	300,000	$	412,000	$	—	$	—	$	—	$	712,000
President and Chief Operating Officer	2023	$	162,500	$	—	$	—	$	—	$	—	$	162,500
Michael A. Gordon⁽¹⁾	2024	$	250,000	$	412,000	$	—	$	—	$	—	$	662,000
General Counsel and Corporate Secretary	2023	$	250,000	$	—	$	—	$	—	$	—	$	250,000

Name and Address of Beneficial Owner ⁽¹⁾	Amount and Nature of Beneficial Ownership			Percent of Class
Directors and Officers:
Lishan Aklog, M.D.		1,541,627	⁽²⁾		1.5	%
Dennis M. McGrath		1,393,569	⁽²⁾		1.3	%
Shaun M. O’Neil		876,763	⁽³⁾			*
Michael A. Gordon		900,000	⁽⁴⁾			*
Stanley N. Lapidus		467,142	⁽⁵⁾			*
James L. Cox, M.D.		534,870	⁽⁶⁾			*
Ronald M. Sparks		450,210	⁽⁷⁾			*
Jacque J. Sokolov, M.D.		450,210	⁽⁸⁾			*
Debra J. White		379,883	⁽⁹⁾			*
Dennis A. Matheis		193,301	⁽¹⁰⁾			*
All directors and executive officers as a group (ten individuals)		7,187,575			6.8	%
5% Stockholders:
PAVmed Inc.		31,302,440	⁽¹¹⁾		29.7	%

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights		Weighted- average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
	(a)		(b)		(c)
Equity compensation plans approved by security holders		8,123,458	$	1.76		1,126,293	⁽¹⁾
Equity compensation plans not approved by security holders		523,300	$	0.46		—
Total		8,646,758	$	1.68		1,126,293	⁽²⁾